Sumayya Naz, MD
Neurology · Toledo, OHNPI 1699327346
Payments from drug & device makers
Across 83 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$252
- SK Life Science, Inc.$249
- Bristol Myers Squibb$176
- Neurelis, Inc.$146
- Argenx US, Inc.$99
- AbbVie$76
- plus $501 from 19 others
What the payments were for
- Food & beverage$1,498100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 14 | $252 |
| SK Life Science, Inc. | 14 | $249 |
| Bristol Myers Squibb | 11 | $176 |
| Neurelis, Inc. | 8 | $146 |
| Argenx US, Inc. | 3 | $99 |
| AbbVie | 4 | $76 |
| Pfizer | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Lundbeck LLC | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Biogen | 2 | $33 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| MDD US Operations, LLC | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $18 |
| Biocodex, Inc. | 1 | $15 |
| CSL Behring | 1 | $15 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,498 in reported general payments places this provider in the 50th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobazam | 13 | $2,477 |
| Lacosamide | 19 | $2,205 |
| Levetiracetam | 24 | $1,241 |
| Divalproex Sodium ErDivalproex Sodium | 22 | $951 |
| Sumatriptan Succinate | 12 | $97 |
Paid to pharmacies, not to this prescriber.
Other neurology in Toledo
- Lawrence ElmerToledo$1.5M
- Mouhammad JumaaToledo$1.1M
- Howard SchechtToledo$564K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.